Are substance-induced psychosis and primary psychosis fundamentally different? And if they are, does it matter?

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

Jefferies analyst Akash Tewari lowered the firm’s price target on Bristol Myers (BMY) to $68 from $70 and keeps a Buy rating on the shares ...

The therapy showed a two-point reduction in total PANSS score at week six against placebo with atypical antipsychotic.

Four former foster youth, now adults, talk about how psychiatric medications impacted their childhoods, and life after meds.

(Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference in a keenly ...

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Squibb announced topline results from the Phase 3 ARISE trial evaluating the efficacy and safety of Cobenfy as an ...

A recent study by researchers at Rutgers University and Columbia University has found a serious link between certain mental ...

Significant weight gain is a common side effect of many psychiatric medications. Fortunately, there are options for those who ...